- Home
- IRT vs AKRO Comparison
IRT vs AKRO Comparison
Compare IRT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- AKRO
- Stock Information
- Founded
- IRT 2009
- AKRO 2017
- Country
- IRT United States
- AKRO United States
- Employees
- IRT N/A
- AKRO N/A
- Industry
- IRT Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- AKRO Health Care
- Exchange
- IRT Nasdaq
- AKRO Nasdaq
- Market Cap
- IRT 3.9B
- AKRO 4.5B
- IPO Year
- IRT 2013
- AKRO 2019
- Fundamental
- Price
- IRT $17.12
- AKRO $54.35
- Analyst Decision
- IRT Strong Buy
- AKRO Buy
- Analyst Count
- IRT 6
- AKRO 10
- Target Price
- IRT $22.17
- AKRO $73.56
- AVG Volume (30 Days)
- IRT 3.3M
- AKRO 1.4M
- Earning Date
- IRT 10-29-2025
- AKRO 11-07-2025
- Dividend Yield
- IRT 3.98%
- AKRO N/A
- EPS Growth
- IRT N/A
- AKRO N/A
- EPS
- IRT 0.09
- AKRO N/A
- Revenue
- IRT $662,924,000.00
- AKRO N/A
- Revenue This Year
- IRT $4.19
- AKRO N/A
- Revenue Next Year
- IRT $4.72
- AKRO N/A
- P/E Ratio
- IRT $187.44
- AKRO N/A
- Revenue Growth
- IRT 3.19
- AKRO N/A
- 52 Week Low
- IRT $15.07
- AKRO $21.34
- 52 Week High
- IRT $22.13
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- IRT 63.68
- AKRO 67.46
- Support Level
- IRT $16.31
- AKRO $54.22
- Resistance Level
- IRT $17.22
- AKRO $54.41
- Average True Range (ATR)
- IRT 0.30
- AKRO 0.14
- MACD
- IRT 0.09
- AKRO -0.18
- Stochastic Oscillator
- IRT 92.47
- AKRO 88.42
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.